Literature DB >> 18790821

Key clinical features to identify girls with CDKL5 mutations.

Nadia Bahi-Buisson1, Juliette Nectoux, Haydeé Rosas-Vargas, Mathieu Milh, Nathalie Boddaert, Benoit Girard, Claude Cances, Dorothée Ville, Alexandra Afenjar, Marlène Rio, Delphine Héron, Marie Ange N'guyen Morel, Alexis Arzimanoglou, Christophe Philippe, Philippe Jonveaux, Jamel Chelly, Thierry Bienvenu.   

Abstract

Mutations in the human X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been shown to cause infantile spasms as well as Rett syndrome (RTT)-like phenotype. To date, less than 25 different mutations have been reported. So far, there are still little data on the key clinical diagnosis criteria and on the natural history of CDKL5-associated encephalopathy. We screened the entire coding region of CDKL5 for mutations in 183 females with encephalopathy with early seizures by denaturing high liquid performance chromatography and direct sequencing, and we identified in 20 unrelated girls, 18 different mutations including 7 novel mutations. These mutations were identified in eight patients with encephalopathy with RTT-like features, five with infantile spasms and seven with encephalopathy with refractory epilepsy. Early epilepsy with normal interictal EEG and severe hypotonia are the key clinical features in identifying patients likely to have CDKL5 mutations. Our study also indicates that these patients clearly exhibit some RTT features such as deceleration of head growth, stereotypies and hand apraxia and that these RTT features become more evident in older and ambulatory patients. However, some RTT signs are clearly absent such as the so called RTT disease profile (period of nearly normal development followed by regression with loss of acquired fine finger skill in early childhood and characteristic intensive eye communication) and the characteristic evolution of the RTT electroencephalogram. Interestingly, in addition to the overall stereotypical symptomatology (age of onset and evolution of the disease) resulting from CDKL5 mutations, atypical forms of CDKL5-related conditions have also been observed. Our data suggest that phenotypic heterogeneity does not correlate with the nature or the position of the mutations or with the pattern of X-chromosome inactivation, but most probably with the functional transcriptional and/or translational consequences of CDKL5 mutations. In conclusion, our report show that search for mutations in CDKL5 is indicated in girls with early onset of a severe intractable seizure disorder or infantile spasms with severe hypotonia, and in girls with RTT-like phenotype and early onset seizures, though, in our cohort, mutations in CDKL5 account for about 10% of the girls affected by these disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18790821     DOI: 10.1093/brain/awn197

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  75 in total

Review 1.  X chromosome inactivation in clinical practice.

Authors:  Karen Helene Orstavik
Journal:  Hum Genet       Date:  2009-04-25       Impact factor: 4.132

Review 2.  Autism spectrum disorder and epilepsy: Disorders with a shared biology.

Authors:  Bo Hoon Lee; Tristram Smith; Alex R Paciorkowski
Journal:  Epilepsy Behav       Date:  2015-04-19       Impact factor: 2.937

3.  The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy.

Authors:  Stephanie Fehr; Meredith Wilson; Jenny Downs; Simon Williams; Alessandra Murgia; Stefano Sartori; Marilena Vecchi; Gladys Ho; Roberta Polli; Stavroula Psoni; Xinhua Bao; Nick de Klerk; Helen Leonard; John Christodoulou
Journal:  Eur J Hum Genet       Date:  2012-08-08       Impact factor: 4.246

Review 4.  Epilepsy genetics--past, present, and future.

Authors:  Annapurna Poduri; Daniel Lowenstein
Journal:  Curr Opin Genet Dev       Date:  2011-01-27       Impact factor: 5.578

Review 5.  Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review.

Authors:  Heather E Olson; Scott T Demarest; Elia M Pestana-Knight; Lindsay C Swanson; Sumaiya Iqbal; Dennis Lal; Helen Leonard; J Helen Cross; Orrin Devinsky; Tim A Benke
Journal:  Pediatr Neurol       Date:  2019-02-23       Impact factor: 3.372

Review 6.  Seizures and X-linked intellectual disability.

Authors:  Roger E Stevenson; Kenton R Holden; R Curtis Rogers; Charles E Schwartz
Journal:  Eur J Med Genet       Date:  2012-02-08       Impact factor: 2.708

7.  West syndrome caused by homozygous variant in the evolutionary conserved gene encoding the mitochondrial elongation factor GUF1.

Authors:  Ali Abdullah Alfaiz; Verena Müller; Nadia Boutry-Kryza; Dorothée Ville; Nicolas Guex; Julitta de Bellescize; Clotilde Rivier; Audrey Labalme; Vincent des Portes; Patrick Edery; Marianne Till; Ioannis Xenarios; Damien Sanlaville; Johannes M Herrmann; Gaétan Lesca; Alexandre Reymond
Journal:  Eur J Hum Genet       Date:  2015-10-21       Impact factor: 4.246

8.  Neurodevelopmental and neurobehavioral characteristics in males and females with CDKL5 duplications.

Authors:  Przemyslaw Szafranski; Sailaja Golla; Weihong Jin; Ping Fang; Patricia Hixson; Reuben Matalon; Daniel Kinney; Hans-Georg Bock; William Craigen; Janice L Smith; Weimin Bi; Ankita Patel; Sau Wai Cheung; Carlos A Bacino; Paweł Stankiewicz
Journal:  Eur J Hum Genet       Date:  2014-10-15       Impact factor: 4.246

9.  Expression pattern of cdkl5 during zebrafish early development: implications for use as model for atypical Rett syndrome.

Authors:  Marta Vitorino; Nídia Cunha; Natércia Conceição; M Leonor Cancela
Journal:  Mol Biol Rep       Date:  2018-05-11       Impact factor: 2.316

10.  CDKL5 and ARX mutations in males with early-onset epilepsy.

Authors:  Ghayda M Mirzaa; Alex R Paciorkowski; Eric D Marsh; Elizabeth M Berry-Kravis; Livija Medne; Asem Alkhateeb; Art Grix; Elaine C Wirrell; Berkley R Powell; Katherine C Nickels; Barbara Burton; Andrea Paras; Katherine Kim; Wendy Chung; William B Dobyns; Soma Das
Journal:  Pediatr Neurol       Date:  2013-05       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.